Gerald Selda-Enriquez

Trichoscopy is a useful tool for diagnosis of tinea capitis. However, the findings are often non-specific and it can be mistaken with other diseases. The implementation of ultraviolet light during trichoscopy may facilitate clinicians to diagnose this disease early and to target the dermatophyte involved according to fluorescence characteristics. It may also help to identify the trichoscopic findings of ectothrix or endothrix infections. In addition, it allows to target specific treatment depending on the findings, being helpful for the cure of the patients.

Citation: Naharro-Rodríguez J, Selda-Enríquez G, García-Mouronte E, Pérez-González LA, Teresa-Dianzo I, Fernández-González P. Monkeypox Infection Mimicking Oral Primary Syphilis. Dermatol Pract Concept. 2023;13(4):e2023222. DOI: https://doi.org/10.5826/dpc.1304a222 Accepted: April 16, 2023; Published: October 2023 Copyright: ©2023 Naharro-Rodríguez et al. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (BY-NC-4.0), https://creativecommons.org/licenses/by-nc/4.0/, which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original authors and source are credited. Funding: None. Competing Interests: None. Authorship: All authors have contributed significantly to this publication. Corresponding Author: Jorge Naharro-Rodríguez, Dermatology Department, Ramon y Cajal University Hospital IRYCIS. Colmenar Viejo km 9.100, 28034 Madrid, Spain. Phone no.: +34627654405; FAX +34913062268. Email: jorgenrmed@gmail.com This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Introduction. Androgenetic alopecia (AGA), the most common form of hair loss in women, is characterized by progressive hair thinning and loss of terminal hairs over frontal and parietal regions of the scalp. This study aimed to evaluate the efficacy of the nutritional supplement Pilopeptan® WOMAN 5αR (PPT5α) composed of specific plant extracts, vitamins, and minerals in women with initial to moderate AGA. Methods. This was a prospective, randomized, double‐blind, placebo‐controlled clinical trial study. Forty‐seven women (aged 25–59 years) with AGA grade I/II were randomized to daily receive PPT5α (n = 24) or placebo (n = 23), and the treatment safety, as well as the percentages of terminal hair in frontal and parietal areas from trichoscopic images, was assessed at 0, 3, and 6 months. Secondary outcomes included self‐assessed hair parameters and overall treatment satisfaction. Results. A total of 44 women completed the study. At 6 months, patients who received the nutritional supplement showed high percentages of terminal hair both in the frontal (77.6% vs 69.8%, p = 0.02) and parietal (77% vs 64.3%, p = 0.02) areas compared to the placebo group. Self‐assessed evaluation of hair parameters showed an improvement in the reduction of hair loss and hair thickness both at the 3‐month (p = 0.004 and p = 0.012) and 6‐month (p = 0.009 and p = 0.004) visits. At the 3 month visit, the intervention group also showed higher treatment satisfaction (p = 0.01). No significant adverse events were reported. Conclusion. These results evidence that the nutritional supplement PPT5α may be beneficial in preventing progression or even improving the condition of AGA in the early stages.

Click on the article title to read more.

Citation: Selda-Enriquez G, Melian-Olivera AL, Burgos-Blasco P, Ortega-Quijano D. Abdominal wall postherpetic pseudohernia. Dermatol Pract Concept. 2021;11(1):e2020096. DOI: https://doi.org/10.5826/dpc.1101a96 Accepted: June 8, 2020; Published: 2020 Copyright: ©2020 Selda-Enriquez et al. TThis is an open-access article distributed under the terms of the Creative Commons Attribution License BY-NC-4.0, which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original author and source are credited. Funding: None. Competing interests: The authors have no conflicts of interest to disclose. Authorship: All authors have contributed significantly to this publication. Corresponding author: Gerald Selda-Enriquez, MD, Servicio de Dermatología, Hospital Universitario Ramón y Cajal, Carretera Colmenar Viejo km 9.100, 28034 Madrid, Spain. Email: geraldselda@gmail.com

Background A previous study has defined the maculopapular subtype of manifestations of COVID‐19. Objectives To describe and classify maculopapular eruptions associated with COVI‐19. Methods We carried out a subanalysis of the maculopapular cases found in the previous cross‐sectional study. Using a consensus, we defined 7 clinical patterns. We described patient demographics, the therapy received by the patient and the characteristics of each pattern. Results Consensus lead to the description of 7 major maculopapular patterns: Morbilliform (45.5%), Other maculopapular (20.0%), Purpuric (14.2%), Erythema multiforme‐like (9.7%), Pytiriasis rosea‐like (5.7%), Erythema elevatum diutinum‐like (2.3%) and Perifollicular (2.3%). In most cases, maculopapular eruptions were coincident (61.9%) or subsequent (34.1%) to the onset of other COVID‐19 manifestations. The most frequent were cough (76%), dyspnea (72%), fever (88%), and astenia (62%). Hospital admission due to pneumonia was frequent (61%). Drug intake was frequent (78%). Laboratory alterations associated with maculo‐papular eruptions were high C‐reactive protein, high D‐Dimer, lymphopenia, high ferritin, high LDH, and high IL‐6. Limitations The impossibility to define the cause–effect relationship of each pattern. Conclusion We provide a description of the cutaneous maculopapular manifestations associated with COVID‐19. The cutaneous manifestations of COVID‐19 are wide‐ranging and can mimic other dermatoses.